Company intelligence / Profile preview

IntelliStem

Toronto, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

IntelliStem's proprietary Super Sentinel Cells™ (SSC) have demonstrated safety and therapeutic potential in human studies, offering an allogeneic, off-the-shelf cell therapy for cancers. Their approach is designed to treat solid and liquid tumors with lower toxicity and higher accessibility versus patient-specific CAR-T products.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Stem cell therapyCell therapyGenetically engineered cell therapyMonoclonal antibody
Industry: Biotech

Partnerships

MÉDIMABS Inc. (for monoclonal antibody discovery)

Beyond the preview

Go deeper on IntelliStem.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IntelliStem.

Explore the full profile